{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:46:32Z","timestamp":1792169192148,"version":"4.4.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009756","name":"Sarcoma UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010307","name":"Chelsea and Westminster Health Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010307","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,11,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Kaposi\u2019s sarcoma (KS) is the most common malignancy occurring in people living with HIV (PLWH). The clinical course of KS in PLWH established on combined anti-retroviral therapy (cART) resembles that of classic KS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      To compare the clinical and biological characteristics of HIV-associated KS in patients with well-controlled viral infection (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200921) and non-HIV-associated KS (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200919).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical data were prospectively collected from patients treated at the National Centre for HIV malignancies at Chelsea &amp; Westminster Hospital. Targeted transcriptomic analysis and multiplex immune-fluorescence were performed on archival tumour samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Clinical outcomes were comparable between groups. The tumour microenvironment (TME) of non-HIV-associated KS was characterised by transcriptional upregulation of pathways associated with adaptive and innate immunity and angiogenesis. The TME of HIV-associated cases was associated with lower infiltration of activated CD4 cells. In both cohorts, we found the expression of HHV-8 genes to positively correlate with activated CD4, CD8, NK and immune checkpoint gene expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The KS TME in the presence of well-controlled HIV infection is characterised by a lower degree of inflammation and more pronounced epithelial to mesenchymal transition. We also identified intra-tumoral HHV-8 gene expression as a driver of TME composition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03536-5","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:01:10Z","timestamp":1785898870000},"page":"1544-1553","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In-depth characterisation of the tumour microenvironment reveals HHV-8-dependent immune regulation in HIV-associated and classic Kaposi sarcoma"],"prefix":"10.1038","volume":"135","author":[{"given":"Claudia A. M.","family":"Fulgenzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Dalla Pria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto Giovanni","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignazio","family":"Puccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista S.","family":"Tuohinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4ivi M.","family":"Ojala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3529-0103","authenticated-orcid":false,"given":"David J.","family":"Pinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"3536_CR1","doi-asserted-by":"crossref","unstructured":"Mariggio G, Koch S, Schulz TF. Kaposi sarcoma herpesvirus pathogenesis. Philos Trans R Soc Lond B Biol Sci. 2017;372:20160275.","DOI":"10.1098\/rstb.2016.0275"},{"key":"3536_CR2","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1086\/507648","volume":"194","author":"A Guihot","year":"2006","unstructured":"Guihot A, Dupin N, Marcelin AG, Gorin I, Bedin AS, Bossi P, et al. Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. J Infect Dis. 2006;194:1078\u201388.","journal-title":"J Infect Dis"},{"key":"3536_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04130-6","volume":"21","author":"MR Openshaw","year":"2023","unstructured":"Openshaw MR, Gervasi E, Fulgenzi CAM, Pinato DJ, Dalla Pria A, Bower M. Taxonomic reclassification of Kaposi Sarcoma identifies disease entities with distinct immunopathogenesis. J Transl Med. 2023;21:283.","journal-title":"J Transl Med"},{"key":"3536_CR4","doi-asserted-by":"crossref","unstructured":"Dalla Pria A, Pinato DJ, Bracchi M, Bower M. Recent advances in HIV-associated Kaposi sarcoma. F1000Research. 2019;8:F1000-aculty.","DOI":"10.12688\/f1000research.17401.1"},{"key":"3536_CR5","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/cncr.35110","volume":"130","author":"L Rajdev","year":"2024","unstructured":"Rajdev L, Jackie Wang CC, Joshi H, Lensing S, Lee J, Ramos JC, et al. Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study. Cancer. 2024;130:985\u201394.","journal-title":"Cancer"},{"key":"3536_CR6","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S1470-2045(22)00097-3","volume":"23","author":"J Delyon","year":"2022","unstructured":"Delyon J, Biard L, Renaud M, Resche-Rigon M, Le Goff J, Dalle S, et al. PD-1 blockade with pembrolizumab in classic or endemic Kaposi\u2019s sarcoma: a multicentre, single-arm, Phase 2 study. Lancet Oncol. 2022;23:491\u2013500.","journal-title":"Lancet Oncol"},{"key":"3536_CR7","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.annonc.2022.03.012","volume":"33","author":"A Zer","year":"2022","unstructured":"Zer A, Icht O, Yosef L, Avram D, Jacobi O, Fenig E, et al. Phase II single-arm study of nivolumab and ipilimumab (Nivo\/Ipi) in previously treated classical Kaposi sarcoma (cKS). Ann Oncol. 2022;33:720\u20137.","journal-title":"Ann Oncol"},{"key":"3536_CR8","doi-asserted-by":"publisher","first-page":"4125","DOI":"10.1200\/JCO.2016.69.3812","volume":"34","author":"MN Polizzotto","year":"2016","unstructured":"Polizzotto MN, Uldrick TS, Wyvill KM, Aleman K, Peer CJ, Bevans M, et al. Pomalidomide for symptomatic Kaposi\u2019s sarcoma in people with and without HIV infection: a Phase I\/II study. J Clin Oncol. 2016;34:4125\u201331.","journal-title":"J Clin Oncol"},{"key":"3536_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-019-0060-9","volume":"5","author":"E Cesarman","year":"2019","unstructured":"Cesarman E, Damania B, Krown SE, Martin J, Bower M, Whitby D. Kaposi sarcoma. Nat Rev Dis Primers. 2019;5:9.","journal-title":"Nat Rev Dis Primers"},{"key":"3536_CR10","doi-asserted-by":"publisher","first-page":"e1012233","DOI":"10.1371\/journal.ppat.1012233","volume":"21","author":"DA Rauch","year":"2025","unstructured":"Rauch DA, Ramos PV, Khanfar M, Harding J, Joseph A, Fahad A, et al. Single-cell transcriptomic analysis of Kaposi sarcoma. PLoS Pathog. 2025;21:e1012233.","journal-title":"PLoS Pathog"},{"key":"3536_CR11","doi-asserted-by":"publisher","unstructured":"Meng W, Das A, Sinha H, Naous R, Bracci PM, McGrath M, et al. Spatial single-cell atlas reveals KSHV-driven broad cellular reprogramming, progenitor expansion, immune and vascular remodeling in Kaposi\u2019s sarcoma. bioRxiv [Preprint]. 2025. Available from: https:\/\/doi.org\/10.1101\/2025.09.01.673567.","DOI":"10.1101\/2025.09.01.673567"},{"key":"3536_CR12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/cid\/ciaa1137","volume":"73","author":"F Caby","year":"2021","unstructured":"Caby F, Guiguet M, Weiss L, Winston A, Miro JM, Konopnicki D, et al. CD4\/CD8 Ratio and the risk of Kaposi sarcoma or non-hodgkin lymphoma in the context of efficiently treated human immunodeficiency virus (HIV) infection: a collaborative analysis of 20 European cohort studies. Clin Infect Dis. 2021;73:50\u20139.","journal-title":"Clin Infect Dis"},{"key":"3536_CR13","doi-asserted-by":"publisher","first-page":"e1008681","DOI":"10.1371\/journal.ppat.1008681","volume":"16","author":"SJ Lidenge","year":"2020","unstructured":"Lidenge SJ, Kossenkov AV, Tso FY, Wickramasinghe J, Privatt SR, Ngalamika O, et al. Comparative transcriptome analysis of endemic and epidemic Kaposi\u2019s sarcoma (KS) lesions and the secondary role of HIV-1 in KS pathogenesis. PLoS Pathog. 2020;16:e1008681.","journal-title":"PLoS Pathog"},{"key":"3536_CR14","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8852221","volume":"2020","author":"O Ngalamika","year":"2020","unstructured":"Ngalamika O, Munsaka S. Cells of the innate and adaptive immune systems in Kaposi\u2019s sarcoma. J Immunol Res. 2020;2020:8852221.","journal-title":"J Immunol Res"},{"key":"3536_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cytogfr.2020.02.004","volume":"55","author":"H Loucif","year":"2020","unstructured":"Loucif H, Dagenais-Lussier X, Beji C, Telittchenko R, Routy JP, van Grevenynghe J. Plasticity in T-cell mitochondrial metabolism: a necessary peacekeeper during the troubled times of persistent HIV-1 infection. Cytokine Growth Factor Rev. 2020;55:26\u201336.","journal-title":"Cytokine Growth Factor Rev"},{"key":"3536_CR16","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.chom.2011.10.011","volume":"10","author":"F Cheng","year":"2011","unstructured":"Cheng F, Pekkonen P, Laurinavicius S, Sugiyama N, Henderson S, Gunther T, et al. KSHV-initiated notch activation leads to membrane-type-1 matrix metalloproteinase-dependent lymphatic endothelial-to-mesenchymal transition. Cell Host Microbe. 2011;10:577\u201390.","journal-title":"Cell Host Microbe"},{"key":"3536_CR17","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1002\/ijc.33163","volume":"147","author":"RAA Santarelli","year":"2020","unstructured":"Santarelli RAA, Gilardini Montani MS, Romeo MA, Gaeta A, Gonnella R, Faggioni A, et al. KSHV dysregulates bulk macroautophagy, mitophagy and UPR to promote endothelial to mesenchymal transition and CCL2 release, key events in viral-driven sarcomagenesis. Int J Cancer. 2020;147:3500\u201310.","journal-title":"Int J Cancer"},{"issue":"Mar","key":"3536_CR18","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1158\/0008-5472.CAN-11-3067","volume":"72","author":"PE-FG Gasperini","year":"2012","unstructured":"Gasperini PE-FG, McCormick PJ, Salvucci O, Maric D, Uldrick TS, Polizzotto MN, et al. Kaposi sarcoma herpesvirus promotes endothelial-to-mesenchymal transition through Notch-dependent signaling. Cancer Res. 2012;72(Mar):1157\u201369.","journal-title":"Cancer Res"},{"key":"3536_CR19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.cytogfr.2014.06.001","volume":"25","author":"K Brulois","year":"2014","unstructured":"Brulois K, Jung JU. Interplay between Kaposi\u2019s sarcoma-associated herpesvirus and the innate immune system. Cytokine Growth Factor Rev. 2014;25:597\u2013609.","journal-title":"Cytokine Growth Factor Rev"},{"key":"3536_CR20","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1038\/s41388-020-1317-1","volume":"39","author":"W Li","year":"2020","unstructured":"Li W, Wang Q, Qi X, Guo Y, Lu H, Chen Y, et al. Viral interleukin-6 encoded by an oncogenic virus promotes angiogenesis and cellular transformation by enhancing STAT3-mediated epigenetic silencing of caveolin 1. Oncogene. 2020;39:4603\u201318.","journal-title":"Oncogene"},{"key":"3536_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvr.2021.200223","volume":"12","author":"MM Gaglia","year":"2021","unstructured":"Gaglia MM. Kaposi\u2019s sarcoma-associated herpesvirus at 27. Tumour Virus Res. 2021;12:200223.","journal-title":"Tumour Virus Res"},{"key":"3536_CR22","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/infdis\/jiaa180","volume":"222","author":"A Jary","year":"2020","unstructured":"Jary A, Leducq V, Desire N, Petit H, Palich R, Joly V, et al. New Kaposi\u2019s sarcoma-associated herpesvirus variant in men who have sex with men associated with severe pathologies. J Infect Dis. 2020;222:1320\u20138.","journal-title":"J Infect Dis"},{"key":"3536_CR23","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/ijd.14563","volume":"58","author":"N Kluger","year":"2019","unstructured":"Kluger N, Blomqvist C, Kivela P. Kaposi sarcoma in Southern Finland (2006-2018). Int J Dermatol. 2019;58:1258\u201363.","journal-title":"Int J Dermatol"},{"key":"3536_CR24","doi-asserted-by":"publisher","first-page":"9654","DOI":"10.1128\/JVI.01049-16","volume":"90","author":"F Ye","year":"2016","unstructured":"Ye F, Zeng Y, Sha J, Jones T, Kuhne K, Wood C, et al. High glucose induces reactivation of latent Kaposi\u2019s sarcoma-associated herpesvirus. J Virol. 2016;90:9654\u201363.","journal-title":"J Virol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03536-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03536-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03536-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:57:22Z","timestamp":1792166242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03536-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,11,5]]}},"alternative-id":["3536"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03536-5","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CAMF received lecture fees from AstraZeneca and Eisai, and consultancy fees from MAIA biotechnology. MB received lecture fees from ViiV and Gilead Sciences, and institutional grants from Gilead Sciences. DJP received consulting fees from Mina Therapeutics, EISAI, Roche, Avamune, DaVolterra, Mursla, H3B, Ipsen, Boston Scientific, Starpharma, Exact Sciences, AstraZeneca, and LIfT Biosciences, and has received honoraria from Roche, BMS, EISAI, and Boston Scientific, and travel support from Roche, BMS, and MSD; received institutional grants from BMS, MSD, and GSK. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Informed consent for publication of anonymised data was obtained from the study participants.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}}]}}